Premium
Si RNA ‐targeted carboxypeptidase D inhibits hepatocellular carcinoma growth
Author(s) -
Jin Tao,
Fu Jie,
Feng XiaoJun,
Wang ShouMei,
Huang Xue,
Zhu MingHua,
Zhang ShuHui
Publication year - 2013
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.10113
Subject(s) - hccs , cancer research , hepatocellular carcinoma , gene knockdown , cell cycle , downregulation and upregulation , apoptosis , cell growth , biology , cirrhosis , microbiology and biotechnology , medicine , gene , biochemistry , genetics
Carboxypeptidase D (CPD), a membrane‐bound metallocarboxypeptidase that functions as a docking receptor for duck hepatitis B virus, is frequently overexpressed in human cancers. We have explored its expression pattern, clinical significance, and biological function of CPD in hepatocellular carcinoma (HCC). CPD expression was markedly elevated in HCCs relative to adjacent non‐tumor liver tissues, as determined by quantitative real‐time polymerase chain reaction and Western blot analysis. Immunohistochemistry showed that 164 of 400 (41%) HCCs had high expression of CPD. CPD overexpression was significantly associated with serum levels of hepatitis B surface antigen and hepatitis B e antigen, liver cirrhosis, pathological grade, and intrahepatic metastasis. Knockdown of endogenous CPD expression in Huh7 HCC cells by RNA interference reduced cell proliferation, blocked the cell cycle at G1 phase, and increased apoptosis. Many genes implicated in cell‐cycle regulation, including P21waf1, P27 Kip1, SKP2, and CDC2, were deregulated by CPD downregulation. Thus CPD is frequently upregulated in HCC, and targeting CPD inhibits HCC cell proliferation through induction of G1 cell‐cycle arrest and apoptosis, thereby providing a potential therapeutic target for this malignancy.